Since 2012 Samsung Biologics and Biogen have collaborated through Samsung Bioepis Co., Ltd., our joint venture to develop, manufacture and market biosimilars of advanced biologics. The strategic collaboration between the two companies has enabled Samsung Bioepis to build the capabilities needed to develop high-quality biosimilars. At the end of 2013, Biogen announced that it had entered into an agreement with Samsung Bioepis to commercialise anti-TNF biosimilar product candidates in Europe, including biosimilars for widely-used therapies to treat conditions such as rheumatoid arthritis, psoriasis and Crohn’s disease. In 2014, the European Medicines Agency (EMA) accepted Samsung Bioepis' marketing authorisation application (MAA) for a biosimilar version of etanercept. In November 2015, the Committee for Medicinal Products for Human Use adopted a positive opinion for this biosimilar.
In March 2015, Samsung Bioepis received acceptance of an MAA for a biosmilar version of infliximab.